5 results about "Protamine sulfate" patented technology

The invention discloses a preparation method of protamine sulfate, and belongs to the field of biological medicine. The preparation method of the protamine sulfate comprises the following steps: S1, crushing mature testis tissues of aquatic organisms, adding saline water, stirring I and filtering I to obtain a salt extracting solution; s2, adding water and polyethyleneimine into the salt extracting solution, stirring II, and filtering II to obtain filtrate; s3, adding water and polyethyleneimine into the filtrate, stirring III, standing I, and pouring supernate to obtain an oily substance at the lower layer; s4, an ammonium sulfate solution is added into the oily matter, stirring IIII and standing II are conducted, supernate is poured out, oily matter at the bottom is obtained and dried, and protamine sulfate is obtained. The preparation method has the advantages of no use of inorganic acid, high purity, small pollution, reagent saving and low cost, and the obtained protein has good activity.

The invention provides an insulin aspart 50 injection and a preparation method thereof, and belongs to the field of pharmaceutical preparations, the insulin aspart 50 injection comprises the following components: insulin aspart: protamine sulfate: glycerol: m-cresol: phenol: sodium chloride: disodium hydrogen phosphate = 100,000 IU: (0.21-0.42 g): (16-20 g): (1.5-2 g): (1-2 g): (0.8-1 g): (1-1.5 g), and the pH value is 7.0-7.8. The preparation method is simple in preparation process, scientific and reasonable, and the preparation method is suitable for industrial production. The preparation method is simple and easy to operate, the prepared insulin aspart 50 injection has the advantages of high stability and good drug effect, the insulin aspart in the injection exists in two forms, one form is in a solution and plays a quick-acting role, and the other form is in a solution. One of the two insulin preparations is combined with protamine sulfate to form a precipitate, and has the time phase characteristic of medium-efficiency insulin, so that the insulin preparation has the action characteristics of two insulin preparations, great convenience is brought to diabetics, and the injection frequency and the pain and inconvenience caused by the injection frequency are reduced.

The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.

This invention discloses a recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, and its preparation method. Recombinant human (or bovine) basic fibroblast growth factor gel is a genetically engineered topical drug used clinically to promote healing of burn wounds, chronic wounds, and fresh wounds, with significant efficacy. However, its drawbacks include limited antibacterial properties and inability to be used simultaneously with chemical disinfectants such as iodine and ethanol, which, while promoting wound healing, are not conducive to controlling wound infection. Research has found that protamine sulfate or polylysine, with high safety and good antibacterial properties, can exert good antibacterial and anti-infection functions without negatively affecting the bioactivity and stability of recombinant human (or bovine) basic fibroblast growth factor. This represents an advanced method for preparing recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, enabling this type of drug to better exert its clinical effects and expand its application scope.

The present invention discloses the use of a cationic compound in the preparation of a hematopoietic stem cell or progenitor cell mobilizer; the cationic compound is hexamethonium bromide (HEX) or protamine sulfate (PRO). In the present invention, the cationic compounds HEX or PRO are used to prepare a hematopoietic stem / progenitor cell mobilizer, and the mobilization levels of hematopoietic stem cells and progenitor cells in peripheral blood are both significantly enhanced, with good mobilization effects. The present invention provides a hematopoietic stem cell and / or progenitor cell mobilization strategy option with clinical transformation potential, enabling more patients to benefit from the treatment.